Imugene Announces Board Changes Amid Cancer Therapy Focus

Imugene Limited (AU:IMU) has released an update.

Imugene Limited, a clinical-stage immuno-oncology company, has announced the resignation of Jens Eckstein from its board. Eckstein, who contributed significantly to the company’s growth since 2019, is stepping down to focus on other business ventures. Investors and stakeholders will be watching closely as Imugene continues its ambitious efforts in pioneering cancer treatments.

For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.